A move to open up competition in drugs would have been one of the few things in Obamacare worth having. It was not to be as big pharma bought off Obama and Democratic senators to keep it from happening.
An amendment to open up competition in drug pricing was narrowly defeated in the Senate Vote-a-Rama last night, but that defeat was not binding by any means.
More importantly, Trump’s Drug-Price Stance Puts Pharma on Notice.
No comments:
Post a Comment